{"prompt": "['Subject Initials:', 'Subject Study ID:', 'Enrolling investigator signature/date', '4.7 Eligibility Criteria', 'No waivers of protocol eligibility will be granted, but when clinical factors relating to an eligibility item', 'are unclear or questionable, the MCW PI can only provide guidance or clarification on eligibility.', 'Medical Inclusion Criteria', '1.', 'Subjects with newly diagnosed acute myeloid leukemia who are eligible', 'for treatment with CPX-351 therapy according to the FDA approval and', 'indication: therapy-related AML (t-AML) or AML with myelodysplasia-', 'related changes (AML-MRC).', '2.', 'Age > 18 years', '3. ECOG of 0 or 1 (or Karnofsky Performance Status equivalent of 70 or', 'above).', '4. Total bilirubin < 3 mg/dL.', '5. Creatinine clearance > 30mL/min by Cockcroft/Gaul equation.', '6. Adequate cardiac function (ejection fraction > 50%) for anthracycline', 'therapy, assessed by ejection fraction via MUGA or echocardiogram.', '7. Total WBC of VI 20,000/uL on peripheral blood assessment (hydrea', 'and/or leukapheresis allowed).', '8. No evidence of active, uncontrolled infection.', '9. No evidence of clinically significant disseminated intervascular', 'coagulation', '10. No clinically significant abnormalities in core vital signs like heart rate,', 'blood pressure or oxygenation which require inpatient evaluation or', 'monitoring.', '11. In the opinion of the enrolling physician, the subject is not at risk for', 'clinically significant tumor lysis syndrome based on clinical assessment,', 'CBC (complete blood count), CMP (comprehensive metabolic panel),', 'uric acid, and LDH.', '12. In the opinion of the enrolling physician, no medical conditions that', 'preclude the subject or the primary caregiver from transportation to and', 'from the outpatient clinical care facility.', '13. Both subject and the identified primary caregiver(s) signed informed', 'consent.', '14. In the opinion of the enrolling physician, there are no medical', 'contraindications to outpatient induction and management.', '15. Male subjects, even if surgically sterilized (i.e., status post vasectomy),', 'must agree to one of the followings:', 'Practice effective barrier contraception during the entire study period', 'and through 90 days after the last dose of CPX-351,', 'OR', 'Agree to practice true abstinence when this is in line with the preferred', 'and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar,', 'ovulation, symptothermal, postovulation methods] and withdrawal are', 'not acceptable methods of contraception.)', 'Female subjects must meet one of the followings:', 'Postmenopausal for at least one year before enrollment,', 'OR', 'MCW Protocol No:IIT-Michaelis-OutpatientCPX-351', 'p24', 'Version No.: 3', 'Version Date: 04/15/2020']['Subject Initials:', 'Subject Study ID:', 'Enrolling investigator signature/date', 'Surgically sterile (i.e., undergone a hysterectomy or bilateral', 'oophorectomy),', 'OR', 'If the subject is of childbearing potential (defined as not satisfying', 'either of the above two criteria), she must agree to practice two', 'acceptable methods of contraception (combination methods require', 'use of two of the following: diaphragm with spermicide, cervical cap', 'with spermicide, contraceptive sponge, male or female condom,', 'hormonal contraceptive) from the time of signing of the informed', 'consent form through 90 days after the last dose of CPX-351, OR', 'Agree to practice true abstinence when this is in line with the', 'preferred and usual lifestyle of the subject. (Periodic', 'abstinence [e.g., calendar, ovulation, symptothermal,', 'postovulation methods] and withdrawal are not acceptable', 'contraception methods.)', 'Logistical Inclusion Criteria', '1. The subject must be able to reside within approximately 45 minutes of', 'the hospital where induction therapy is administered, during normal', 'driving conditions (in the opinion of the enrolling physician), until count', 'recovery or 60 days post-treatment, whichever comes first', '2. The enrolling physician must verify and attest that the subject has a', 'primary caregiver meeting all the following criteria:', '2.1 Reside with the subject.', '2.2 Be able to care for the subject full time or arrange to share full-', 'time care with secondary caregivers.', '2.3 Provide transportation.', '2.4 Respond to clinical issues that arise.', '2.5 Communicate with subject and physician in a timely manner.', '2.6 Age > 18 years', '3. The nurse teacher must verify that the subject and primary caregiver', 'have completed and adequately understand the study-dictated nurse', 'teacher educational program.', '4.', 'The nurse teacher must verify the subject and primary caregiver have', 'capacity to comply with outpatient management program.', '5. The subject must have reliable, working telephone access.', '6. The subject must be willing and able to attend all protocol-dictated visits', 'and be seen frequently as an outpatient at the clinical care facility where', 'induction therapy is administered.', 'Exclusion Criteria', '1. Pregnant women (per pregnancy test in women of childbearing potential)', 'or women who are breast-feeding.', '2. Subjects currently receiving any investigational agents.', '3. Subjects must not have current evidence of another malignancy that', 'requires treatment.', \"4. Subjects diagnosed with Wilson's disease and/or copper-related\", 'metabolic disorders.', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p25', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}